New drug trial offers hope for patients with Hard-to-Treat kidney disease

NCT ID NCT06781944

Summary

This study is testing if a newer drug called obinutuzumab works better than the current standard treatment for primary membranous nephropathy, a serious autoimmune kidney disease. It will involve about 144 adults whose disease is still active despite initial medication. The main goal is to see which treatment helps more patients achieve remission, meaning a major reduction in harmful protein leaking into their urine, over two years.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Huashan Hospital, Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 200040, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.